Forte Biosciences, Inc. (FBRX)
NCM · Healthcare · Biotechnology
$17.56
+0.92%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$359.6M
Shares Outstanding
20.5M
Exchange
NCM
Currency
USD
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -11.6M | -18.4M | -24.6M | -22.4M |
| Net Income | -11.2M | -17.7M | -24.8M | -22.1M |
| Diluted EPS | $-0.96 | $-0.99 | $nan | $-1.24 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -13.9M | -32.5M | -36.6M | -70.7M |
| Net Income | -13.9M | -31.5M | -35.5M | -69.4M |
| Diluted EPS | $-20.00 | $-24.92 | $-12.17 | $-4.71 |